The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options
Explore this paper's citation graph
Summary
Many different combinations and sequences of therapies can be offered to patients with in-transit extremity melanoma in the contemporary era, and reported response and survival rates of the varied treatments may offer valuable information regarding treatment decisions.
- Type
- review
- Published
- 2015-07-01
- Cited by
- 27
- References
- 142
- Access
- Open access
- OpenAlex
- https://openalex.org/W1565001940
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:9017846
Keywords
Medicine, Melanoma, Disease, Systemic therapy, Intensive care medicine
References
- In-transit melanoma: an individualized approach.
- Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
- Management of in‐transit metastases from cutaneous malignant melanoma
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
- An isolated limb infusion technique: a guide for the perfusionist.
- Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
- The role of adjuvant radiotherapy in the local management of desmoplastic melanoma
- Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
- OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
- Imiquimod: mode of action
- Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus
- Isolated Limb Infusion as a Model to Test New Agents to Treat Metastatic Melanoma
- Treatment of in‐transit melanoma with intra‐lesional interleukin‐2: A systematic review
- Intralesional therapy with PV‐10 (Rose Bengal) for in‐transit melanoma
- Local and intralesional therapy of in‐transit melanoma metastases
- Intralesional therapy for metastatic melanoma
- Intra‐lesional interleukin‐2 therapy for in transit melanoma
- Improved overall survival in melanoma with combined dabrafenib and trametinib.
- Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
- Isolated limb perfusion for malignant melanoma.
Cited by
- Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma
- Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas
- Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series
- Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis.
- MRI-Guided Cryoablation of In-Transit Metastases from Cutaneous Melanoma: A Brief Report on a Preliminary Experience
- MicroRNA‐21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study
- Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study
- Do you know your guidelines? Diagnosis and management of cutaneous head and neck melanoma
- A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma
- Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe
- Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies
- Improved durable responses regardless of age following cytoreduction and “no-tourniquet” hyperthermic isolated limb chemotherapy for in transit melanoma of the extremity.
- Perfusão regional de membros no tratamento quimioterápico de melanoma: uma revisão de literatura
- Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma
- pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy
- Current Management of Melanoma
- Local and regional therapy for primary and locally recurrent melanoma.
- In-transit metastatic cutaneous melanoma: current management and future directions
- Non-Operative Options for Loco-regional Melanoma.
- Advances in the discovery and development of melanoma drug therapies
Related papers
- Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients.
- Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium
- The melanoma epidemic: more apparent than real?
- Preoperative diagnosis of malignant melanoma using the touch-fluorescence method
- Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma-seeking compound.
- Challenges for the radiation oncologist: the role of radiation therapy after primary systemic therapy
- ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma.